Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: A prospective with quality control 10-year follow-up study by Roukos, D H et al.
Despite the well-known universal decline in gastric cancer inci-
dence and mortality, particularly in the USA and Western Europe,
stomach cancer remains an important cause of death, world-
wide. In Far Eastern countries such as China, Japan, and Korea
and also in many developing countries, gastric cancer is the most
prevalent malignant neoplasm and the leading cause of cancer
death (Roukos, 2000a). 
Current reports of treatments for gastric cancer from Japan
(Marujama et al, 1987; Fujii et al, 1999), and Korea (Kim, 1999),
when compared to historical data, suggest a marked improvement
in the overall survival rates. This improvement is attributable to an
earlier detection and, according to Eastern investigators, to a more
radical surgical approach (Marujama et al, 1987; Fujii et al, 1999,
Kim et al, 1999). In Japan, due to a mass screening programme,
the rate of early gastric cancer that is associated with a good prog-
nosis, has increased to 50% and curative resection is possible in up
to 93% of cases (Fujii et al, 1999), whereas these same figures in
the West are only about 15% and 50 to 70% respectively (Roukos,
2000a). Some Western authors support the notion that the better
survival results in the East are exclusively attributable to the early
detection of the disease, and not to the more aggressive surgery
that is employed in the East (Bonenkamp et al, 1999). 
A surgical resection with curative intent, R0 resection according
to the International Union Against Cancer (UICC) (Beahrs et al,
1992), is the treatment of choice for gastric cancer; in that the
prognosis for all other patients with apparently residual tumour
following surgery is extremely poor. However, even after an R0
resection, the proportion of treatment failures for advanced gastric
cancer is substantially high. For the improvement of both local
control and survival, a more extensive surgery is proposed.
However, it is still unclear whether curative resection should
include, besides gastrectomy, an extended lymph node dissection
as occurs in the East. Randomized controlled trials in the West
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Summary UICC classification accurately predicts overall survival but not recurrence-risk. We report here data of overall and first site-specific
recurrence following curative surgery useful for the development of recurrence-oriented preventive target therapies. Patients who underwent
resection for gastric cancer were stratified according to curability of surgery [curative (R0) vs non-curative resection], extent of surgery [limited
(D1) vs extended (D2) node dissection] and pathological nodal/serosal status. The intent-to-treat principle, log-rank test and Cox regression
analysis were used for statistical analysis of time-to-event (recurrence, death) endpoints. Curative resection only produced a chance of cure
whereas survival was very poor following non-curative resection (P < 0.0001). For D2 R0 subgroup of patients, a pathological serosa and a
node state-based classification into three groups, proved to be of clinical implication. Risk of recurrence after a median follow-up of 92 months
was low among patients with both serosa and node-negative cancer (first group; 11%), moderate among those with either serosa or node-
positive cancer (second group; 53%) and very high among those with both serosa and node-positive cancer (third group; 83%). In multivariate
analysis, the relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to those
in the first, were 7.07 (95% CI, 2.36–21.17; P = 0.0002) and 16.19 (95% CI, 5.76–45.54; P < 0.0001) respectively. First site-specific
recurrence analysis revealed: low rate of loco-regional recurrence alone (12%), serosa state determinant factor of the site-recurrence
(peritoneal for serosa-positive and haematogenous for serosa-negative cancers) and dramatic increase of all types of recurrence by the
presence of nodal metastases. Our findings demonstrate that a pathological serosa- and node-based classification is very simple and predicts
accurately site-specific recurrence-risks. Furthermore they reveal that risk of recurrence following curative D2 surgery alone is low for serosa-
and node-negative cancers, but very high in serosa- and node-positive cancers suggesting the need for new therapeutic strategies in this
subgroup of patients. © 2001 Cancer Research Campaign http://www.bjcancer.com
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have failed to demonstrate a survival benefit in favour of D2
dissection (Bonenkamp et al, 1999; Cuschieri et al, 1999), but
there is still uncertainty because of strong criticisms of these trials
(Brennan, 1999; Roukos, 2000b). 
The assessment of the gastric cancer recurrence risk and
outcome is an important and urgent issue, however, cancer and
especially gastric cancer is complicated by the fact that recurrence
occurs in a variety of forms and in different organs following R0
resection; loco-regional, peritoneal, lymph nodal, haematogenous
and combinations of these, constitute the major sites of recurrence.
Therefore, the establishment of an extensive Japanese-style
surgery for the control of the disease in Western patients is of prac-
tical relevance and of even greater social significance because no
adjuvant treatment, that would contribute to survival improve-
ment, has yet been established to be effective (Hermans et al,
1993; Roukos, 2000a). The target of this prospective study, was to
assess the effectiveness of a standardized extensive surgery, by
evaluating risk factors for recurrence and the overall survival of
patients who had previously undergone this surgical approach at a
median follow-up of 92 months. 
PATIENTS AND METHODS 
All consecutive patients with a histologically confirmed gastric
carcinoma who had undergone resection between January 1986
and December 1992 were included in this prospective study. We
excluded patients who had a palliative surgical procedure without
gastrectomy because resection is necessary for accurate histo-
logical diagnosis and staging. Patients were also excluded if they
had a previous or coexisting cancer. 
After surgery, the patients underwent a clinical examination,
laboratory tests, X-rays, endoscopic or radiologic examination and
abdominal ultrasound every 3 months or computer tomography
every 6 months in the first 2 years. Thereafter, all these examina-
tions were performed every 6 months. 
Surgery 
The guidelines of the Japanese Research Society for Gastric
Carcinoma (JRSGC), for the standardization of surgical treatment
and pathological evaluation (Nishi et al, 1995), as well as the
recommendations by the American Joint Committee on Cancer
(AJCC) and the UICC in the fourth edition of their manual for the
staging of cancer (Beahrs et al, 1992), formed the basis of our
protocol. Total gastrectomy with an extended lymph-node dissec-
tion was the treatment of choice. A subtotal gastrectomy (SG) was
only performed in patients with an early stage (T1) intestinal-type
growth pattern, according to the Lauren classification, or in older
patients not in good physical condition. Extended (D2) lymph
node dissection was performed using a systematic and standard-
ized technique according to the guidelines of the JRSGC. D2 node
dissection in our study entailed the removal of perigastric
compartment I nodes (stations 1 to 6, attached to the stomach: D1
dissection) and the extraperigastric compartment II nodes (stations
7 to 12) using a technique previously described (Roukos et al,
1998). The total gastrectomy specimen with greater and lesser
omenta and containing nodal stations 1 through 6, including the
nodes along the left gastric artery (station 7) was removed en-
block and sent to the pathologist. However, the fatty connective
tissue containing nodes from each of the 3 major compartment II
nodal areas, i.e., hepatoduodenal ligament (station 12), superior
border of the pancreas (stations 8, 9 and 11), and spleen hilus 
(station 10), was separately dissected, labeled and sent to the
pathologist. Resection of the spleen was optional. 
Pathology and quality control 
All histopathological data were prospectively documented in a
standardized protocol. The pathological lymph node grouping
(pN) was done according to the rules of the JRSGC slightly
modified in our protocol pN1 stage: detection of metastasis by
pathologist in compartment I lymph nodes (stations 1 through 6),
but no metastases in compartment II; pN2: metastases in compart-
ment II nodes (stations 7 through 12) but no metastases in
compartment III. For tumour invasion (pT), distant metastases
(pM) and curability of resection, the recommendations of the
AJCC/UICC were applied. 
Obviously, the risk of recurrence should only be studied among
patients who had a complete resection in the apparent absence of
remaining disease. Because the curability of resection includes,
besides the resection of the primary tumour, the dissection of
metastatic nodes, we evaluated the risk of relapse among patients
who had an extended (D2) node dissection, which ensures an accu-
rate nodal staging. An objective estimation of the risk of relapse
among patients who had undergone a limited (D1) dissection
appears to be unreliable because a substantial proportion of these
patients have remaining disease after a D1 dissection. This
because it has been shown that compartment II nodes that are left
behind after a D1 resection, are tumour positive in 30% of patients
who had a D2 resection with curative intent (Bunt et al, 1995;
Roukos, 2000a, 2000b). 
We used the pathological and surgical findings documented in
the protocol to stratify patients according to the curability of resec-
tion (curative (R0) or noncurative (R1, R2)) and extent of lymph-
node dissection (D1 or D2) based on standardized criteria. Patients
were classified as having a curative resection if, at laparotomy,
there was no macroscopic evidence of hepatic or peritoneal spread
of the tumour or metastatic deposits beyond the compartment II
nodes, that the resection resulted in complete macroscopic tumour
removal and in the final pathological examination there was no
microscopic evidence of tumour cells in all resection lines. The
patients who met these macroscopic and microscopic criteria
constituted the group treated curatively (R0 resection), all the
others who did not meet these criteria constituted the group treated
with a palliative intent (R1, R2 resection). 
To control the surgical report as to whether a D2 node dissection
was completely performed, we used the pathology report from the
lymph-node examination. For the quality control, the number of
retrieved lymph-nodes per station by the pathologist and the
intrinsic biological variation of nodes per station (Marujama et al,
1987) were considered. Details for this quality control are
described in an our recent report (Roukos et al, 2000). 
It should be noted that none of the patients treated curatively
underwent adjuvant chemotherapy or radiotherapy and thus the
surgery alone is responsible for the reported results. 
Statistical analysis 
All diagnostic, surgical and histopathological data and records of
events (death, recurrence or censored patients) were prospectively
documented on a standardized protocol. The primary endpoints
were recurrence-free survival and overall survival, as measured1604 DH Roukos et al 
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from the date of surgery to the time of the last follow-up visit or
death, irrespective of cause. The treatment effect was primarily eval-
uated according to the intention-to-treat principle and all the patients
were included in the overall survival analysis, irrespective of
whether they had an R0 or R1, R2 resection. Because the survival of
patients who had noncurative surgery is extremely poor and cannot
be affected by any type of surgical or adjuvant treatment, all subse-
quent analyses were focused on the patients who had undergone an
R0 resection. Only the patients who had not died in the hospital after
a D2 curative resection were at risk of recurrence, we therefore only
estimated the risk of recurrence amongst these patients. 
We constructed Kaplan–Meier life-table curves in order to esti-
mate the probability of treatment failure for the endpoints of
disease-free survival and overall survival (Kaplan and Meier,
1958), and used the log-rank test for comparison. Data on patients
who were alive and had no evidence of disease at the end of our
study or at the last follow-up visit were censored. We used a multi-
variate Cox proportional-hazards analysis to estimate the prog-
nostic effect of various variables with respect to relapse-free
survival and overall survival (Cox, 1972). A P value of less than
0.05 was considered to indicate statistical difference. For statistical
analyses, we used SPSS software for Windows (version 9.0.1). 
RESULTS 
Of the 210 patients with gastric carcinoma who underwent gastrec-
tomy, 59 (28%) had a non-curative resection and 151 (72%) under-
went a curative resection. Of these 151 R0 patients, our criteria for
a D2 node dissection were fulfilled by the 124 patients (79%). 
Long-term survival for all resected patients 
All resected patients were included in the primary analysis of
overall survival according to the intention-to-treat principle, irre-
spective of curability (R0, R1/R2 resection). Of 210 resected
patients, 202 (96%) could be followed. During a median follow-up
of 54 months, 139 patients died and 63 were alive without
evidence of recurrence (31.2%). The curability of resection (cura-
tive vs. noncurative, P < 0.001, Figure 1), nodal status (pN-stage,
P < 0.0001), tumour invasion (pT-stage, P < 0.0001) and extent of
surgery (extended vs. limited lymph-node dissection, P < 0.0001)
were all significant prognostic factors according to the log-rank
test in univariate analysis. In a step-down multivariate analysis, the
nodal status (P < 0.0001) and the curability of resection (P =
0.0001) were found to be the strongest significant and independent
predictors of outcome. 
Further analysis of the results according to the curability of
resection shows that the median survival time following noncura-
tive resection was very poor (8 months). The relative risk of death
among palliatively resected patients, as compared with those who
had a curative resection, was 2.32 (95% confidence interval, 1.53 to
3.52). Since the prognosis of patients with residual disease after resec-
tion was extremely poor, and that this dismal survival unfortunately
cannot be improved by any type of surgery, we estimated the effect of
extensive surgery on loco-regional or any type of recurrence and
survival on patients who had a D2 resection with curative potential. 
Survival of patients who had a D2 curative lymph-node
dissection 
Table 1 shows the clinical and tumour characteristics. Most of
patients (91%) had a total gastrectomy and an advanced pathological
T3-cancer (53%). Of the 124 patients who fulfilled our criteria for
a D2 resection with curative intent, there were only 2 postoperative
in-hospital deaths (1.6%). One patient was lost to follow-up
(0.8%). Of the 121 patients who left the hospital and thus were at
risk of relapse, during a median follow-up of 92 months for survi-
vors, gastric cancer recurred in 59 patients (49%). The median
time from surgery to the evidence of recurrence or death from
gastric cancer for these 59 patients was 10 months (73% recurred
within the first two years and only 5% after the fifth year; mean
survival time 17.24 months (range 1 to 70). These 59 patients died
shortly after the first evidence of recurrence (median time, 5
months (range 0 to 33)). 
Table 2 shows the sites of first recurrence and status of patients
at their last follow-up according to the serosa and lymph node
state. The frequency of any type of recurrence increased with
serosa invasion and the presence of lymph-node metastases. There
was no difference between the intestinal-type and diffuse-type
cancer according to the Lauren-classification in any type of recur-
rence. Evidence of the first site of relapse was obtainable in 34
patients (58%), whereas it was impossible in the remaining 25
patients because of the rapid progression of the disease from
surgery to death with multiple metastases in different organs.
Among these 34 patients, loco-regional recurrence as the only
cause of a first relapse, was rarely assessed (12%), whereas perito-
neal or haematogenous recurrences were more frequently evident
(88%). Peritoneal dissemination as the only site of recurrence was
the most frequent treatment failure (29%). 
There was a strong correlation between serosa state and the type
of recurrence. Peritoneal recurrence occurred exclusively among
patients with serosa invasion, whereas none of the serosa-negative
cancers had a peritoneal relapse. This figure persisted even though
we calculated all patients who had peritoneal failure alone or in
combination with other organ recurrences. Of the 20 patients with
peritoneal recurrence alone or in combination with other organs,
19 had a serosa invasion (95%) and only one (5%) had a serosa-
negative cancer (pT2 tumour). Interestingly, in 88% of the
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Figure 1 Kaplan–Meier survival curves for patients with gastric cancer
stratified according to the curability of resection. The survival of patients who
had a curative resection (R0) was significantly better than that of patients
who had a non-curative resection (R1, R2) (P < 0.0001) Gastric cancer recurrence and prognosis 1605
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patients, the evidence of first recurrence was exclusively confined
to the abdominal cavity. However, 29% of these patients had
multiple recurrences in different organs (peritoneal surface, liver,
local) (Table 2). 
Both the lymph-node status (pN category) and tumour invasion
(pT category) were found to be significant factors in the prediction
of both relapse-free survival and overall survival, whereas the
location of the tumour and the Lauren classification had no prog-
nostic relevance in univariate analysis (Table 3). In a Cox multi-
variate regression analysis, nodal status and tumour invasion were
each found to be significant and independent predictors of both
recurrence and gastric cancer-related death (P = 0.002 and 
P = 0.005, respectively), and of death of any cause (P = 0.002
and P = 0.02 respectively) (Table 4). 
Pathological serosa and node state-based 
risk-prediction analysis 
Since microscopic nodal and wall invasion (pN, pT categories)
were found to be independent predictors of survival and that
there was a strong correlation between the serosa status and site
of first recurrence, we performed a recurrence and death risk-
prediction analysis with a combination of both prognostic vari-
ables to assess whether this combination could more accurately
predict both the risk of relapse and death from any cause. From
the stratification of the patients according to both serosa and
nodal state derived 4 groups: serosa-, and node-negative cancers
(pT1, 2N0, first group), serosa-positive but node-negative cancer
(pT3N0, group B1), serosa-negative but node-positive cancer (pT1, 2
N1, 2, group B2) and serosa- and node-positive cancers (pT3N1,2, third
group). It was found that there was no significant difference
between the patients in groups B1 and B2 with respect to either
relapse-free survival (P = 0.72) or overall survival (P = 0.38) and
thus these 2 subgroups were included in the same group (second
group; pT3N0, pT1, 2 N1,2). 
Of 47 patients in the third group, 39 recurred and died (83%),
whereas of 32 in the second group, 16 recurred and died (50%).
Among 42 patients in the first group only 4 recurred and died
(10%) (Table 2). As shown in Figure 2, after 10 years of follow-
up, patients in the first group were at low risk (11%), those of
second group at high risk (53%) and those of the third group at
very high risk (83%) of recurrence and death from gastric cancer.
The differences between the 3 groups in both risk of recurrence
and death from gastric cancer or death from any cause were, by
log-rank test, highly significant (P < 0.0001). 
We performed a Cox multiple-regression analysis, entering
these 3 groups into the model (Table 5). This classification accu-
rately predicted both the cumulative risks of recurrence and
death from gastric cancer and of death from any cause. The rela-
tive risks of recurrence and death from gastric cancer among
patients in the second and third groups, as compared to that in
first group, were 7.07 (95% confidence interval (CI, 2.36–21.17;
P = 0.0005) and 16.19 (95% CI, 5.76–45.54; P < 0.0001) respec-
tively). 
DISCUSSION 
Our results confirm that curative resection (R0) is a very strong
and independent predictor of outcome for gastric cancer. The
survival for all other patients with remaining disese after resection
is extremely poor and cannot be improved by any type of treat-
ment, thus our study focused on patients who had an R0 resection.
Although surgery with curative potential is without doubt the
treatment of choice, controversy still remains as to the optimal
extent of this resection. The hypothesis for the improvement of
both local control and survival and the favourable findings with
respect to an extended lymph node dissection in reports from East
(Marujama et al, 1987; Fujii et al, 1999; Kim, 1999), and West
(Siewert et al, 1998), have not been confirmed by 2 recent
European randomized trials (Bonenkamp et al, 1999; Cuschieri
et al 1999). Controlled trials are the best method for making
treatment decisions (Sackett et al, 1996), but criticism regarding
their appropriateness of design and conduct (Brennan, 1999;
Roukos, 2000b). Have lead now to an uncertainty over the optimal
extent of surgery. We conducted this study in order to assess the
potential of a Japanese-type radical surgery in Western patients.
Because experience and pancreas preservation are predominant
factors for both the safety and completeness of an extended lymph
node dissection (Siewert et al, 1998; Brennan, 1999; Roukos,
2000b), we started this study after gaining 7 years experience with
D2 dissection (Roukos et al, 1990). This strategy and the low rate
of pancreatectomies explains the low rate of in-hospital mortality
(1.6%) in our study, which is similar to that of other reports
(Marujama et al, 1987; Siewert et al, 1998; Fujii et al, 1999; Kim,
1999) suggesting the safety of the D2 procedure when the criteria of
a surgeon’s experience and pancreas-preserving technique are met.
The low rate of in-hospital mortality with a high rate of prospective
Table 1 Characteristics of 124 patients who underwent a D2 resection with
curative potential (R0) 
Variable No. of patients percent 
All patients 124 
Median age (range) 65 (29–86) 
Sex (M/F) 77/47 
Location of tumour 
Cardia, upper third 34 27.5 
Middle third 41 33 
Distal third 41 33 
More than two thirds 8 6.5 
Depth of invasion (UICC/AJCC)a
Serosa-negative cancers 58 46.8 
pT1 25 20.2 
pT2 33 26.6 
Serosa-positive cancer (pT3) 66 53.2 
Lymph node status (JRSGC)b
Node-negative cancers (pN0) 60 48.4 
Node-positive cancer 64 51.6 
pN1 33 26.6 
pN2 31 25 
Lauren classification 
Intestinal 48 38.7 
Diffuse or mixed type 76 61.3 
Type of gastrectomy 
Total 113 91 
Subtotal 11 9 
Resection of spleen 67 54 
Resection of tail of pancreas 7 5.6 
aThe tumour-node-metastasis classification of the Union International contre
le Cancer (UICC) and the American Joint Committee on Cancer, 4th edition
was used.6
bThe nodal stage of the Japanese Research Society for Gastric Cancer, 1st
English edn. was used.12 The abbreviation pT, pN denotes pathologically
confirmed tumour-nodes. 1606 DH Roukos et al 
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Table 2 Types of recurrences and status of patients at last follow-up according to serosa and lymph nodes state of patients who had undergone a curative D2
resection
Numbers of patients (percent) 
Site of relapse No. of patients Serosa-negative cancer (pT1, T2) Serosa-positive cancer (pT3) 
Node-negative Node-positive  Node-negative  Node-positive   
(pN0) (pN1, N2) (pN0) (pN1, N2)
Patients at risk of relapse 121 42 (35) 15 (12) 17 (14) 47 (39) 
Recurrences 59 (49) 4 (10) 8 (53) 8 (47) 39 (83) 
First site undefined 25 (42) 2 6 1  16 
First site clearly defined 34 (58) 2 2  7 23 
Loco-regional alone 4 (12) 0 1 1  2 
Distant metastases 30 (88) 2 1 6  21 
Peritoneal alone 10 (29) 0 0 1 (14)  9 (39) 
With local 3 0 0 2 1 
With liver 7 1 0 1 5 
Liver alone 6 (11) 0 0 2 4 
Extra-abdominal alone or with intra-abdominal failure 4 (20) 1 1 0 2 
Status of patients at last follow-up 
All patients 124 42 16 18 48 
Alive 
Without recurrence 51 (41) 33 (79) 4 (25)  8 (44) 6 (13) 
With recurrence 0 
Dead 72 9 (21) 12 (75) 10 (56) 41 (87) 
Recurrence 59 (49) 4 (10) 8 (53) 8 (47) 39 (83) 
In-hospital postoperatively 2 (1.6) 0 1  1 0 
Cause other than gastric cancer 11 (10) 5 3  1 2 
Lost to follow-up 1 (0.8) 0 0 0  1 
aFirst site of recurrence could not be diagnosed due to rapid progression with multiple recurrences in different organs. 
Table 3 Univariate analysis of predictive factors for relapse and death or death from any cause in patients with gastric cancer who had a curative D2 resection 
Variable Relapse-free survivala Overall survivalb
n = 121 n = 123 
No. of  5-Yr % 10-Yr % P Valuec No. of   5-Yr % 10-Yr % P Valuec
Patients Patients
Events/Total Events/Total
Location of tumor 0.10 0.25 
Upper third stomach 17/34 48 48 21/34 41 35 
Middle third 18/40 57 53 23/40  50 40 
Distal third 17/39 57 53 21/41  51 44 
More than two thirds 7/8 – –  7/8 – – 
Lauren classification 0.42 0.79 
Intestinal-type cancer 20/46 55 51 28/47 44 35 
Diffuse or mixed type 39/75 50 47 44/76 52 39 
Tumour invasiond <0.0001 <0.0001 
pT1 2/24 91 91 4/25 88 82 
pT2 10/33 64 64 17/33 53 44 
pT3 47/64 31 26 51/65 32 19 
Lymph-node statuse <0.0001 <0.0001 
pN0 12/59 80 78 19/60 74 64 
pN1 22/33 31 31 25/33 33 23 
pN2 25/29 19 10 28/30 17 5 
Of 124 patients, one was lost to follow-up. aPatients who left the hospital were at risk of recurrence. This analysis included all 121 patients who did not die in
hospital; 2 in-hospital deaths were excluded. bThis analysis included all 123 patients who were at risk of death due to any cause including the 2 in-hospital
deaths. cThe log-rank test was used. dPathological tumour stage according to UICC/AJCC system.6e Pathological nodal stage according to JRSGC
classification.12Gastric cancer recurrence and prognosis 1607
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documentation of all events, allows a follow-up in nearly all of the
patients enrolled in the study. 
UICC/AICC classification predicts accurately overall survival but
is not able to predict overall recurrence and site-specific recurrence-
risks. A recurrence-risk prediction analysis on patients who had an
R0 resection is important in determining both the potential and
limitations of surgery and therefore in making decisions about the
need for adjuvant treatment. Our study confirms the predictive value
of tumour depth (pT-category) and nodal status (pN-category);
however, both a pathological serosa and node state-based classifica-
tion of patients into 3 major subgroups proved to be of clinical
significance for 3 reasons. 
Firstly, this classification was highly accurate in predicting
recurrence-risk and death among patients who had either both
serosa and node negative cancer (first group, low risk; 11%) or
both positive (third group, very high risk; 83%). The difference in
the risk of treatment failure between these two groups was highly
significant in multivariate analysis (relative risk 16.19, 95% CI
5.76–45.54; p < 0.0001). However, in the second group of patients
with either serosa- or node-positive cancer, this predictive value
was not high (53%).
Secondly, a serosa and node state-based classification proved
useful in predicting the site of first recurrence-risk. Obtaining
Table 4 Cox multivariate proportional-hazards analysis for patients who had a D2 resection with curative intenta
Variable Relapse and deathb Death from any causec
n = 121 n = 123 
P value Relative risk (95% CI) P value Relative risk (95% CI) 
Lymph-node statusd 0.002 0.002 
pN1 vs pN0 0.009 2.70 (1.28–5.73) 0.01 2.20 (1.16–4.19) 
pN2 vs pN0 0.0005 3.77 (1.78–7.99) 0.0004 3.23 (1.68–6.19) 
Tumour invasione 0.005 0.02 
pT2 vs pT1 0.19 2.81 (0.59–13.40) 0.08 2.73 (0.89–8.44) 
pT3 vs pT1 0.01 6.81 (1.51–30.84) 0.01 4.18 (1.38–12.67) 
aOf 124 patients, one was lost to follow-up. bThis analysis included all 121 patients who were at risk of relapse; 2 in-hospital deaths were
excluded. All 59 patients who relapsed died shortly after the evidence of recurrence (median time, 5 months). cThis analysis included all 123
patients who were at risk of death of any cause including the 2 in-hospital deaths. dPathological nodal stage (pN) according to JRSGC
classification.12 ePathological tumour stage (pT) according to UICC/AJCC system.6 The abbreviation CI denotes the confidence interval. 
Table 5 Cox-multivariate proportional-hazards analysis of patients who had a curative D2 resection stratified according to both the serosa
and node statea
Variable Recurrence and deathb Death from any causec
n = 121 n = 123 
P value Relative risk (95% CI) P value Relative risk (95% CI) 
Pathological serosa and node stated <0.0001 <0.0001 
Either serosa or node-positive  0.0005 7.07 (2.36–21.17) 0.0002 4.32 (1.99–15.27) 
(pT3 N0 or pT1,2 N1,2) vs both negative (pT1,2 N0)
Both serosa and node-positive  <0.0001 16.19 (5.76–45.54) <0.0001 7.35 (3.55–15.21) 
(pT3 N1,2) vs both negative (pT1,2 N0)
aOf 124 patients, one was lost to follow-up. bPatients were stratified according to the pathological evidence of serosa invasion (pT3) or not
(pT1, pT2) and the presence of lymph-node metastases (pN1, pN2) or not (pN0). Pathological tumour staging was done according to
UICC/AJCC system, 4th edition,6 and nodal staging (pN) according to JRSGC.12 cThis analysis included all 121 patients who were at risk of
relapse; the 2 in-hospital deaths were excluded. All of the 59 patients who relapsed died shortly after the evidence of recurrence (median
time, 5 months). dThis analysis included all 123 patients who were at risk of death through any cause including the 2 in-hospital deaths. 
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Figure 2 Kaplan–Meier relapse-free survival curves for patients with gastric
cancer, stratified according to both the pathological serosa- and node-state
based classification. The differences in the cumulative risks of recurrence
and death from gastric cancer between the 3 groups of patients with both
serosa- and node-negative cancer (first group; pT1,2 N0) or either serosa- or
node-positive cancer (second group; pT3N0, pT1,2, N1,2) or both positive
cancer (third group; pT3 N1,2) were highly significant (P < 0.0001) 1608 DH Roukos et al 
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evidence for the first site of recurrence in gastric cancer is chal-
lenging because it occurs rapidly after an R0 resection in a variety
of forms and in different organs (Maehara et al, 2000). Indeed, we
were only able to provide evidence of the first site of failure in
only 58% of cases. An intensive monitoring for increased early
detection of first site recurrence is of no practical value since the
dismal prognosis of recurrent gastric cancer can not be altered by
any type of treatment. Despite these difficulties, the data contained
within our study and that of other reports (Averbach and Jacquet,
1996; Nakajima et al, 1999; Maehara et al, 2000), clearly indicate
a strong correlation between the serosa state and peritoneal recur-
rences. This is the most common type of treatment failure among
serosa-positive patients, but it rarely occurs among serosa-
negative patients for whom a haematogenous recurrence is the
most frequent. 
Thirdly, the potential of surgery proved to be closely related to
the serosa and node state-based classification. Surgery alone
resulted in excellent survival for most patients with both serosa-and
node-negative cancer. These patients had a very good prognosis
(mean overall survival time 103 months; ± 6; 95% CI 91 to 114
months), similar to that of Eastern reports (Marujama et al, 1987;
Fujii et al, 1999; Kim, 1999), suggesting the reproducibility of
Japanese results in the West for this subgroup of patients. A further
improvement of outcome with adjuvant treatment appears, at
present, unrealistic. The ineffectiveness of adjuvant chemotherapy
(mitomycin, fluorouracil, uracil, tegafur) that was proven in a
recent controlled trial for serosa-negative cancer and a possible
adverse effect of drugs on the host immune surveillance system
(Nakajima et al, 1999) do no support the use of adjuvant chemo-
therapy in these patients. However, surgery was proven to be less
effective in the 2 other groups, accounting for 65% of the total of
our R0 patients. At 10 years after surgery, 32% and 12% only of
patients were alive in the second and third groups respectively.
These survival rates are substantially lower compared to the
Japanese reports. The likely explanation for this treatment differ-
ence is still unclear, although it has been suggested to be attribut-
able to stage migration according to Western investigators
(Bonenkamp et al, 1999) or to a more extensive surgery resulting in
a better control and survival according to Japanese investigators
(Fujii et al, 1999). Indeed, we assessed that overall, there was a low
rate of loco-regional recurrence (12%), which was distinctly lower
compared to reports from USA with limited surgery (40%)
(Wanebo et al, 1993), but overall survival was poor. These findings
suggest the potential of extensive surgery in reducing loco-regional
failure, but clearly indicate its limitation in affecting distant recur-
rences and clinical outcome. Theoretically, the most likely explana-
tion for this high treatment failure rate among patients with
advanced gastric cancer who had a surgically complete tumour
resection, is the presence of undetected disseminated tumour cells
or distant micrometastases at the time of surgery. This view is
strongly supported by the low rate of local failure and an early
distant recurrence after an R0 resection in our study. The systemic
component of the disease has been demonstrated even in its early
stages, at best for breast cancer (Braun et al, 2000), and shown to be
stage-dependent. However, the prognostic significance of these
findings is still to proven (Zippelins et al, 2000). 
Ideally, the establishment of the prognostic value of dissemi-
nated tumour cells and that of biologic new tumour prognostic
factors may lead to a more effectively tailored therapy towards indi-
vidual patients. A sophisticated staging would also help us to under-
stand the critical question why some patients develop recurrences
and others do not, although they had similar clinical and conven-
tional tumour characteristics and had underwent the same appro-
priate treatment. The systemic component of the disease and the
ineffectiveness of postoperative, late chemotherapy administration
(Hermans et al, 1993; Averbach and Jacquet, 1996; Roukos,
2000a), justifies the research interest focused in testing the effi-
cacy of neoadjuvant (preoperative) or intraoperative intraperito-
neal chemotherapy for the prevention of haematogenous or
peritoneal surface recurrences in controlled ongoing trials. 
At present, however, a pathological serosa and node-based clas-
sification into 3 groups is simple, feasible, and realistic in all in-
stitutions. The high value in predicting first site and overall
recurrence and outcome, the highly significant differences
between the 3 groups, and the determination of potential and limi-
tations of extensive surgery in a strong relation to this classification,
establish it as the key point in daily clinical practice. However, the
validity and the accuracy prediction rate of this classification is
strongly dependent, from the careful, prospective documentation
of all clinicopathologic data and on a quality control in stratifica-
tion of patients according to curability of resection (R0 or R1, R2)
and extent of lymph node dissection (D1 or D2). The appropriate
surgery for patients with serosa and node-negative cancer, leads to
a very good survival rate and there seems to be no further need for
adjuvant treatment. However, in the 2 other patient groups,
survival rates are substantially reduced in a serosa and node stage-
dependent manner. Occult disseminated tumour cells at the point
of surgery are likely to be responsible for high recurrence rates and
poor survival, thus indicating the limitations of surgery in
advanced gastric cancer. Therefore, there is an urgent need for an
adjuvant treatment, but despite great efforts over the last 3
decades, no effective chemotherapy regimen has been established.
An exaggeration in the interpretation in the outcome for patients
with advanced gastric cancer, or, an overoptimism as expressed
recently with the phrase ‘End to cancer in sight...’ is criticized as
being unrealistic; to expect a massive reduction in the mortality
rate on the basis of results of new drugs is also premature, as has
been pointed out in a Lancet Editorial (Lancet, 2000). At present,
early detection and appropriate treatment may contribute to a
substantial reduction in case-fatality in gastric cancer. 
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